Literature DB >> 12772594

Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR.

Masuhiro Nishimura1, Hiroshi Yaguti, Hiroki Yoshitsugu, Shinsaku Naito, Tetsuo Satoh.   

Abstract

Pairs of forward and reverse primers and TaqMan probes specific to each human cytochrome P450 isoform were prepared. Analysis of the mRNA level of each CYP isoform in total RNA from pooled specimens of various human organs was performed by real-time reverse transcription PCR using an ABI PRISM 7700 sequence detector system. The expression of CYP3A4 mRNA was similar to that of CYP3A7 mRNA in the fetal liver, and CYP3A4 mRNA levels in the fetal liver were about 0.1 times lower than in the adult liver. CYP2E1 showed the highest level of mRNA expression in the liver. The mRNA expression of 30 CYP isoforms (CYP1A1, 1A2, 1B1, 2A6, 2A7, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5, 3A7, 4A11, 4F2, 4F3, 5A1, 7B1, 8A1, 8B1, 17, 26A1, 27, 27B1, 39A1, 46, and 51) in the liver was successfully detected by this method. CYP2F1, 4B1, 4F8, 11s (11A, 11B1, and 11B2), 19, and 24 mRNA levels were the highest in the lung, lung, prostate, adrenal gland, placenta, and kidney, respectively; however, the mRNA expression of these eight CYP isoforms in the liver was not detected by this method. The mRNA levels of the CYP isoforms determined in various human tissues were in good agreement with previously reported data. The method described here has the advantages of high specificity and excellent quantification over a wide range of mRNA concentrations, making it suitable for the evaluation of a large number of samples in the assessment of the expression profile of drug-metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12772594     DOI: 10.1248/yakushi.123.369

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  66 in total

1.  Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism.

Authors:  Sabrina A Bardowell; Faping Duan; Danny Manor; Joy E Swanson; Robert S Parker
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.

Authors:  Landry K Kamdem; Ingolf Meineke; Ina Koch; Ulrich M Zanger; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-01       Impact factor: 3.000

3.  PAVA: physiological and anatomical visual analytics for mapping of tissue-specific concentration and time-course data.

Authors:  Michael-Rock Goldsmith; Thomas R Transue; Daniel T Chang; Rogelio Tornero-Velez; Michael S Breen; Curtis C Dary
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-05-22       Impact factor: 2.745

4.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

Review 5.  Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.

Authors:  Stefan Oswald; Christian Gröer; Marek Drozdzik; Werner Siegmund
Journal:  AAPS J       Date:  2013-08-28       Impact factor: 4.009

6.  Nucleolar localization and circadian regulation of Per2S, a novel splicing variant of the Period 2 gene.

Authors:  Daniele Avitabile; Licia Genovese; Donatella Ponti; Danilo Ranieri; Salvatore Raffa; Antonella Calogero; Maria Rosaria Torrisi
Journal:  Cell Mol Life Sci       Date:  2013-11-08       Impact factor: 9.261

7.  Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

8.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

9.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

Review 10.  Bile Acids: A Communication Channel in the Gut-Brain Axis.

Authors:  Vera F Monteiro-Cardoso; Maria Corlianò; Roshni R Singaraja
Journal:  Neuromolecular Med       Date:  2020-10-21       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.